Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Company Description

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.

It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers.

The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.

In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis.

Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software.

It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects.

The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Country	China
Founded	1996
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	948
CEO	Da Jun Zhao

Contact Details

Address: Zhangjiang Hi-Tech Park Shanghai, 201210 China
Phone	86 21 5895 3355
Website	fd-zj.com

Stock Details

Ticker Symbol	1349
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000000W4
SIC Code	2836

Key Executives

Name	Position
Da Jun Zhao	Co-Founder, GM and Chairman
Xue Yan ACCA, CIA, CICPA, FCCA, HKICPA	Chief Financial Officer, Deputy GM, Company Secretary and Director
Jun Li	Co-Founder and Deputy GM
Luo Chun Wang	Core Technical Personnel
Dai Qing Yu	Deputy General Manager
Yu Chen	Deputy General Manager
Xiaowen Li	Deputy General Manager